Share Twitter LinkedIn Facebook Email John Fruehauf, MD of UC Irvine Health explains how INMC data has impacted surgical oncologists. Advertisement
TIL Therapy Breakthroughs for Oncologists and Oncology Professionals Melanoma Skin Cancer Treatment 1 Min Read
63% pCR Rate with Neoadjuvant Nivolumab + Relatlimab in Resectable Melanoma Melanoma Skin Cancer Treatment 4 Mins Read
